|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng R, Zeng H, Zhang S and Chen W:
Estimates of cancer incidence and mortality in China, 2013. Chin J
Cancer. 36:662017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fukushima R: Recent progress in the
treatment of advanced gastric cancer. Nihon Geka Gakkai Zasshi.
113:32012.(In Japanese). PubMed/NCBI
|
|
4
|
Xu JM: Comments on the seven clinical
questions & answers in Japanese gastric treatment guidelines of
the 4th edition. Zhonghua Zhong Liu Za Zhi (Chinese J Oncol).
39:236–238. 2017.
|
|
5
|
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM,
Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, et
al: HER2 screening data from ToGA: Targeting HER2 in gastric and
gastroesophageal junction cancer. Gastric Cancer. 18:476–484. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho J, Jeong J, Sung J, Sung CO, Kim KM,
Park CK, Choi MG, Sohn TS, Bae JM and Kim S: A large cohort of
consecutive patients confirmed frequent HER2 positivity in gastric
carcinomas with advanced stages. Ann Surg Oncol. 20 Suppl
3:S477–S484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim KC, Koh YW, Chang HM, Kim TH, Yook JH,
Kim BS, Jang SJ and Park YS: Evaluation of HER2 protein expression
in gastric carcinomas: Comparative analysis of 1,414 cases of
whole-tissue sections and 595 cases of tissue microarrays. Ann Surg
Oncol. 18:2833–2840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S,
Wang J, Xu N, Cheng Y, Bai Y, et al: Optimal regimen of trastuzumab
in combination with oxaliplatin/capecitabine in first-line
treatment of HER2-positive advanced gastric cancer (CGOG1001): A
multicenter, phase II trial. BMC Cancer. 16:682016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP,
Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, et al: Phase II study of
trastuzumab in combination with S-1 and cisplatin in the first-line
treatment of human epidermal growth factor receptor HER2-positive
advanced gastric cancer. Cancer Chemother Pharmacol. 76:397–408.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brower V: Apatinib in treatment of
refractory gastric cancer. Lancet Oncol. 17:e1372016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kang JH, Lee SI, Lim DH, Park KW, Oh SY,
Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, et al: Salvage
chemotherapy for pretreated gastric cancer: A randomized phase III
trial comparing chemotherapy plus best supportive care with best
supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang EJ, Im SA, Oh DY, Han SW, Kim JS,
Choi IS, Kim JW, Kim YJ, Kim JH, Kim TY, et al: Irinotecan combined
with 5-fluorouracil and leucovorin third-line chemotherapy after
failure of fluoropyrimidine, platinum, and taxane in gastric
cancer: Treatment outcomes and a prognostic model to predict
survival. Gastric Cancer. 16:581–589. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tarazona N, Smyth EC, Peckit C, Chau I,
Watkins D, Rao S, Starling N and Cunningham D: Efficacy and
toxicity of salvage weekly paclitaxel chemotherapy in non-Asian
patients with advanced oesophagogastric adenocarcinoma. Ther Adv
Med Oncol. 8:104–112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guideline Recommendations for HER2
Detection in Gastric Cancer Group: Guidelines for HER2 detection in
gastric cancer (2016). Zhonghua Bing Li Xue Za Zhi. 45:528–532.
2016.PubMed/NCBI
|
|
16
|
Guideline Recommendations for HER2
Detection in Gastric Cancer Group: Guidelines for HER2 detection in
gastric cancer. Zhonghua Bing Li Xue Za Zhi. 40:553–557.
2011.PubMed/NCBI
|
|
17
|
Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM,
Wang ZN, Li HQ, Zhang SB and Sun Z: The clinicopathological
parameters and prognostic significance of HER2 expression in
gastric cancer patients: A meta-analysis of literature. World J
Surg Oncol. 15:682017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kurokawa Y, Sugimoto N, Miwa H, Tsuda M,
Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, et
al: Phase II study of trastuzumab in combination with S-1 plus
cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer.
110:1163–1168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS,
Park SR, Han HS, Chung IJ, Song EK, Lee KH, et al: Multicenter
phase II study of trastuzumab in combination with capecitabine and
oxaliplatin for advanced gastric cancer. Eur J Cancer. 51:482–488.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang FQ: A clinical study of DOF
regimenvsSOX regimen as first-line treatment in patients with
advanced gastric carcinoma. World Chin J Digestol. 22:48302014.
View Article : Google Scholar
|
|
21
|
Cunningham D, Okines AF and Ashley S:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 362:858–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meads DM, Marshall A, Hulme CT, Dunn JA
and Ford HE: The cost effectiveness of docetaxel and active symptom
control versus active symptom control alone for refractory
oesophagogastric adenocarcinoma: Economic analysis of the COUGAR-02
trial. PharmacoEconomics. 34:33–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et
al: Gastric cancer, version 3.2016, NCCN clinical practice
guidelines in oncology. J Natl Compr Cancer Netw. 14:1286–1312.
2016. View Article : Google Scholar
|
|
25
|
Nishikawa K, Takahashi T, Takaishi H, Miki
A, Noshiro H, Yoshikawa T, Nishida Y, Iwasa S, Miwa H, Masuishi T,
et al: Phase II study of the effectiveness and safety of
trastuzumab and paclitaxel for taxane- and trastuzumab-naive
patients with HER2-positive, previously treated, advanced, or
recurrent gastric cancer (JFMC45-1102). Int J Cancer. 140:188–196.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ford HE, Marshall A, Bridgewater JA,
Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S,
Middleton GW, et al: Docetaxel versus active symptom control for
refractory oesophagogastric adenocarcinoma (COUGAR-02): An
open-label, phase 3 randomised controlled trial. Lancet Oncol.
15:78–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thuss-Patience PC, Kretzschmar A, Bichev
D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G
and Reichardt P: Survival advantage for irinotecan versus best
supportive care as second-line chemotherapy in gastric cancer-a
randomised phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sym SJ, Hong J, Park J, Cho EK, Lee JH,
Park YH, Lee WK, Chung M, Kim HS, Park SH and Shin DB: A randomized
phase II study of biweekly irinotecan monotherapy or a combination
of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients
with metastatic gastric adenocarcinoma refractory to or progressive
after first-line chemotherapy. Cancer Chemother Pharmacol.
71:481–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maruta F, Ishizone S, Hiraguri M, Fujimori
Y, Shimizu F, Kumeda S and Miyagawa S: A clinical study of
docetaxel with or without 5′DFUR as a second-line chemotherapy for
advanced gastric cancer. Med Oncol. 24:71–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Satoh T, Xu RH, Chung HC, Sun GP, Doi T,
Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, et al: Lapatinib plus
paclitaxel versus paclitaxel alone in the second-line treatment of
HER2-amplified advanced gastric cancer in Asian populations:
TyTAN-a randomized, phase III study. J Clin Oncol. 32:2039–2049.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen SC, Kagedal M, Gao Y, Wang B,
Harle-Yge ML, Girish S, Jin J and Li C: Population pharmacokinetics
of trastuzumab emtansine in previously treated patients with
HER2-positive advanced gastric cancer (AGC). Cancer Chemother
Pharmacol. 80:1147–1159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yuan M, Shi Z, Wang Z, Lv W, Yang Y, Lu F,
Zhao Y and Zhong H: The significance of multi-line chemotherapy for
advanced gastric cancer: A retrospective analysis. Mol Clin Oncol.
6:606–612. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang W, Yu Y, Fang Y, Wang Y, Cui Y, Shen
K and Liu T: Systemic chemotherapy as a main strategy for liver
metastases from gastric cancer. Clin Transl Oncol. 17:888–894.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase iii trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Moore KN, Martin LP, O'Malley DM,
Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R and Birrer
MJ: Safety and activity of mirvetuximab soravtansine (IMGN853), a
folate receptor alpha-targeting antibody-drug conjugate, in
platinum-resistant ovarian, fallopian tube, or primary peritoneal
cancer: A phase I expansion study. J Clin Oncol. 35:1112–1118.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamasaki M, Saito N, Hada Y, Miyamoto S,
Okanobu H, Ikeda N, Daido W, Ishiyama S, Deguchi N, Taniwaki M and
Ohashi N: Nivolumab therapy for synchronous ALK-positive lung
cancer and gastric cancer. Case Rep Oncol. 10:361–367. 2017.
View Article : Google Scholar : PubMed/NCBI
|
